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 Genetic risk for schizophrenia and psychosis in 
Alzheimer disease 
MAA DeMichele-Sweet, EA Weamer, L Klei1, DT Vrana, DJ Hollingshead, HJ Seltman, R Sims T 
Foroud, I Hernandez, 
INTRODUCTION 
PsǇĐhotiĐ sǇŵptoŵs, deﬁŶed as the oĐĐuƌƌeŶĐe of delusioŶs oƌ halluĐiŶatioŶs, aƌe fƌeƋueŶt iŶ 
Alzheimer disease (AD+psychosis (AD+P)), affecting ~ 40 to 60% of individuals with AD. In 
comparison with AD subjects without psychosis, AD+P subjects have more rapid cognitive decline 
and poor outcomes. Ropacki and Jeste1 comprehensively reviewed the literature on psychosis in AD 
from 1990 to 2003, identifying 55 studies comprising 9749 subjects. More rapid cognitive decline 
ǁas the ŵost ĐoŶsisteŶt Đoƌƌelate of AD+P Đoŵpaƌed ǁith AD ǁithout psǇĐhosis ;AD − PͿ. Moƌe 
recent studies have continued to support the relationship between greater cognitive impairment, 
more rapid cognitive decline and AD+P.2–8 AD+P is further associated with additional psychiatric 
and behavioral disturbances, the most frequent and troublesome of which are agitation9 and 
aggression.10,11 AD+P leads to greater distress for family and caregivers,12 greater functional 
impairment,13 higher institutionalization rates,14–17 worse health18 and increased mortality19 
Đoŵpaƌed ǁith AD − P patieŶts. 
Treatment of psychosis in AD patients has been suboptiŵal ďeĐause of the liŵited efﬁĐaĐǇ of 
available drugs and their highoxicity in this age group. First-line treatments are atypical 
aŶtipsǇĐhotiĐs that haǀe efﬁĐaĐǇ siŵilaƌ to ĐoŶǀeŶtioŶal aŶti-psychotics for AD+P, with lower rates 
of motor side effects.20 However, atypical and conventional antipsychotics have been associated 
with an increased risk of all-cause mortality after even short-term treatment.20,21 Other 
tƌeatŵeŶts, suĐh as seleĐtiǀe seƌotoŶiŶ ƌeuptake iŶhiďitoƌs, ŵaǇ haǀe soŵe efﬁĐaĐǇϮϮ,Ϯϯ aŶd 
improved tolerability.24 Nevertheless, none of these treatments were derived to prevent or reverse 
aŶ ideŶtiﬁed ďiologǇ of AD+P, aŶd theƌe aƌe Ŷo ĐuƌƌeŶt data to suggest that aŶǇ of these tƌeatŵeŶts 
effectively mitigate against the greater cognitive and functional decline associated with AD+P. It is 
thus imperative to develop an approach to promote discovery regarding the biology of AD+P and 
identify opportunities to intervene to prevent its adverse trajectory. 
We initially observed familial aggregation of AD+P,25 since replicated in two independent 
cohorts.4,26 These studies show a remarkable consistency in the estimated three- to fourfold 
increased odds of psychosis in a family member with AD, given the presence of psychosis in a 
proband with AD. Similarly, we used two of these cohorts to estimate the heritability of psychosis in 
AD as ϲϭ%.Ϯϳ,Ϯϴ Thus, AD+P is likelǇ to ďe stƌoŶglǇ iŶﬂueŶĐed ďǇ 
 
 
 
 
 
  
Figuƌe ϭ. Diagƌaŵ of the studǇ desigŶ aŶd ǁoƌkﬂoǁ. ACE, FuŶdaĐió ACE BaƌĐeloŶa Alzheimer 
Treatment and Research Center; ADC, consortium of National Institute on Aging Alzheimer Disease 
CeŶteƌs; AD − P, Alzheiŵeƌ disease ǁithout psǇĐhosis; AD+P, Alzheiŵeƌ disease ǁith psǇĐhosis; 
ADRC, University of Pittsburgh Alzheimer Disease Research Center; CHS, Cardiovascular Health 
Study; GWAS, genome-ǁide assoĐiatioŶ studǇ; NIA LOAD, NatioŶal IŶstitute oŶ AgiŶg͛s Late OŶset 
Alzheiŵeƌ͛s Disease FaŵilǇ StudǇ; NIMH, NatioŶal IŶstitute of MeŶtal Health GeŶetiĐs IŶitiatiǀe AD 
Cohort; SCZ, schizophrenia; SNP, single-nucleotide polymorphism; QC, quality control; UK, Genetic 
and Environmental Risk in AD Consortium 1. 
 
geŶetiĐ ǀaƌiatioŶ. IŶ keepiŶg ǁith these oďseƌǀatioŶs, ǁe ƌeĐeŶtlǇ ƌepoƌted the ﬁƌst geŶoŵe-wide 
association study (GWAS) of AD+P, evaluating 1299 cases with AD+P and 735 individuals 
ĐhaƌaĐteƌized as AD − P. Although Ŷo siŶgle siŶgle-nucleotide polymorphism (SNP) demonstrated 
genome-ǁide sigŶiﬁĐaŶĐe, likelǇ ďeĐause of ŵodest saŵple size, theƌe ǁas suggestiǀe eǀideŶĐe foƌ 
association with novel loci. 
We fuƌtheƌ fouŶd a tƌeŶd toǁaƌd assoĐiatioŶ ǁith a gƌoup of ϭϭ SNPs that had ďeeŶ ideŶtiﬁed iŶ 
iŶitial GWAS studies of sĐhizophƌeŶia aŶd ďipolaƌ disoƌdeƌ.Ϯϵ That latteƌ ﬁŶdiŶg also pƌoǀided the 
biologically intriguing observation that the direction of 7/11 allelic effects on risk for AD+P were 
opposite to that reported in the studies of psychiatric disorder subjects. Since the time of our prior 
ƌepoƌt, geŶoŵiĐ studies of sĐhizophƌeŶia ƌisk haǀe ideŶtiﬁed ϭϮϴ SNPs iŶ ϭϬϴ loĐi that eǆĐeed 
genome-ǁide sigŶiﬁĐance.30 
Recently, the use of polygenic risk scores has emerged as an important approach for summarizing 
genetic effects of a set of SNPs. A polygenic score is a simple, subject-speĐiﬁĐ suŵŵaƌǇ of the 
additive effects of alleles on a trait. When computed to pƌediĐt suďjeĐts͛ ƌisk foƌ a disoƌdeƌ, it is 
called a polygenic risk score. The score can be obtained from a limited set of SNPs, such as those 
reaching genome-ǁide sigŶiﬁĐaŶĐe iŶ assoĐiatioŶ studies oƌ a laƌgeƌ set ďased oŶ soŵe otheƌ 
threshold31–33 or the entire genome.34,35 For example, when alleles at the 108 schizophrenia-
associated loci were combined in a polygenic risk score, they explained 3.4% of the liability to 
schizophrenia.30 For traits in which few or no individual SNPs reach genome-wide signiﬁcance, 
polygenic risk scores can provide initial evidence for true genetic association of the trait with the 
SNPs either included within the ndividual affected loci. 
Here we follow-up on our prior research in an expanded Discovery Cohort of 2876 AD subjects with 
and without psychosis. All subjects were genotyped using a custom chip designed to evaluate SNPs 
with evidence of genetic association, mostprominently with AD+P, although SNPs affecting or 
putatively affecting risk for schizophrenia and AD were also assessed. Results were replicated in an 
independent cohort of 2194 AD subjects with and without psychosis. We found that AD+P is 
associated with polygenic risk for a set of novel loci and inversely associated with polygenic risk for 
schizophrenia. We belieǀe these ﬁŶdiŶgs pƌoǀide the ﬁƌst Đleaƌ deŵoŶstƌatioŶ that AD+P is 
associated with common genetic variation. In addition, they provide an unbiased link between 
polygenic risk for schizophrenia and a lower risk of psychosis in AD. As efforts to identify the biologic 
effects of schizophrenia alleles progress, it may be possible to leverage these results to identify 
novel mechanisms protecting against more rapid cognitive decline and psychosis risk in AD. 
MATERIALS AND METHODS 
An overview of the study design aŶd ǁoƌkﬂoǁ is shoǁŶ iŶ Figuƌe ϭ. 
Subjects 
This study analyzed samples obtained from subjects in two cohorts, an initial Discovery Cohort and 
an independent Replication Cohort (Table 1). All subjects were diagnosed with possible, probable36 
oƌ deﬁŶiteϯϳ AD. Importantly, subjects with a primary diagnosis of dementia with Lewy bodies 
(DLB)38 were excluded. The above diagnoses resulted from diagnostic evaluations, cognitive testing 
aŶd iŶ soŵe Đases ŶeuƌopathologiĐ assessŵeŶt ĐoŶduĐted duƌiŶg suďjeĐts͛ paƌtiĐipation in the 
following programs as previously described: the University of Pittsburgh Alzheimer Disease Research 
Center (ADRC),39,40 the Genetic and Environmental Risk in AD Consortium 1 (UK),29,41,42 the 
NatioŶal IŶstitute oŶ AgiŶg͛s Late OŶset Alzheiŵeƌ͛s Disease Family Study (NIA-LOAD),4,28 the 
National Institute of Mental Health Genetics Initiative AD Cohort (NIMH),25 the Fundació ACE 
Barcelona Alzheimer Treatment and Research Center (ACE),41,43 the Cardiovascular Health Study 
(CHS)3,41 and a consortium of National Institute on Aging Alzheimer Disease Centers (ADC).44 
ColleĐtioŶ of ĐliŶiĐal data aŶd geŶetiĐ saŵples ǁeƌe appƌoǀed ďǇ eaĐh site͛s loĐal iŶstitutioŶal ƌeǀieǁ 
board or medical ethics committee, as appropriate. Additional detail of the individual cohorts and 
assessment methodology is available in Supplementary Methods and Supplementary Tables S1–S13. 
Characterization of psychosis 
Subjects were characterized for the presence or absence of delusions and hallucinations within the 
individual studies using the CERAD (Consortium to Establish a Registry for Alzheimer's Disease) 
behavioral rating scale45 (ADRC and NIA-LOAD), Neuropsychiatric Inventory Questionnaire (NPI-
Q,46 NIA-LOAD, ADC), NPI-Q Spanish Version47 (ACE), NPI48 (UK, CHS) and Brief Psychiatric Rating 
Scale49 (NIMH). Each of these instruments has established reliability in AD,4,50 and we have 
previously used all successfully in analyses of psychosis in AD subjects.3,4,6,27,39 Details of the 
application of these assessments for each cohort are provided in the Supplementary Methods. AD+P 
ǁas deﬁŶed ďǇ the pƌeseŶĐe of peƌsisteŶt halluĐiŶatioŶs oƌ delusioŶs oĐĐuƌƌiŶg duƌiŶg the Đouƌse of 
the deŵeŶtia, aŶd AD − P ǁas deﬁŶed ďǇ the aďseŶĐe of all sǇŵptoŵs at all assessŵeŶts. BeĐause 
psychotic symptoms typically emerge in the mild to moderate stages of AD,4 individuals without 
psychosis but who were still in the early stages of disease at their last assessment (Clinical Dementia 
Rating51 score o1, Mini–Mental State Examination score52 420) were considered to be at 
substantial risk of developing AD+P later in their course. Thus, these individuals were excluded from 
the aŶalǇsis. We haǀe pƌeǀiouslǇ used these appƌoaĐhes to ĐhaƌaĐteƌiziŶg aŶd deﬁŶiŶg AD+P aŶd AD 
− Pto demonstrate familial aggregation,4,25 heritability,27,28 genetic linkage28,53 and suggestive 
genome-wide association29 with the AD+P phenotype. 
Genotyping 
DNA preparation. Samples from outside sources were shipped on dry ice, stored and processed by 
the Genomic Core Lab at the University of Pittsburgh. ACE samples were supplied as whole blood 
and genomic DNA was extracted using the Qiamp Blood Mini kit (Qiagen, Valencia, CA, USA). All 
other centers provided genomic DNA (ADRC, NIA-LOAD, NIMH, UK, ADCͿ oƌ ǁhole geŶoŵe aŵpliﬁed 
DNA (CHS). 
Custom chip for Discovery Cohort. The Genomic Core Lab quantitated all samples by Pico Green 
;Theƌŵo Fisheƌ, Pittsďuƌgh, PA, USAͿ aŶd diluted the DNA to Ϯϯ Ŷg μl − ϭ aŶd shipped the plates oŶ 
dry ice to Affymetrix (Los Angeles, CA, USA) for genotyping. Plates also contained randomized 
dupliĐates. AffǇŵetƌiǆ ĐoŶﬁƌŵed all DNA ĐoŶĐeŶtƌatioŶs ďǇ PiĐo GƌeeŶ assaǇ ďefoƌe geŶotǇpiŶg. 
Genotyping used a custom-designed Axiom chip (see SNP selection below), and was performed using 
the Affymetrix GeneTitan system as described in the axiom user manual54 with resultant genotype 
calls provided for quality control (QC) and analysis. 
iPlex assay for genotyping SCZ risk score SNPs and Replication Cohort testing iPlex chemistry: Assays 
were designed with Assay Designer 4.0 (Agena, San Diego, CA, USA) and analysis performed using 
iPleǆ Gold GeŶotǇpiŶg ‘eageŶt Set ;AgeŶaͿ aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ͛s iŶstƌuĐtioŶs. Taƌget loĐi 
ǁeƌe aŵpliﬁed ǁithiŶ the saŵples ďǇ ŵultipleǆ PC‘ iŶ ϭ × PC‘ ďuffeƌ ĐoŶtaiŶiŶg ϯ.ϱ ŵM 
MgCl2,25mM dNTPs, 500 nM eaĐh of foƌǁaƌd aŶd ƌeǀeƌse aŵpliﬁĐatioŶ pƌiŵeƌ ǁithiŶ the ŵultipleǆ 
pool and 2.5 U HotStar Taq. The dNTPs and primers were removed by incubation with 0.5 U shrimp 
alkaline phosphotase at 37 °C for 40 min. The shrimp alkaline phosphotase was inactivated by 
incubation at 87 °C for 5 min. Single base extension was carried out in 0.2 × iPLEX buffer plus, 1 × 
teƌŵiŶatioŶ ŵiǆ ;ĐoŶtaiŶiŶg ŵass ŵodiﬁed teƌŵiŶatioŶ ŶuĐleotidesͿ, ϭ × iPLEX eŶzǇŵe aŶd pƌiŵeƌs 
at Ϭ.ϴϰ, ϭ.Ϭϰ aŶd ϭ.Ϯϱ μM as appƌopƌiate to the ƌelatiǀe ŵass of each primer. Following 
thermocycling, clean resin and water was added to the MassExtend (Agena Bioscience, San Diego, 
CA, USA) reaction products. Samples were incubated in clean resin at room temperature with mixing 
for 5minandcentrifugedat3200g for 5 min. 
Samples were then dispensed to a SpectraChip (Agena Bioscience) using the MassArray 
Nanodispenser (Agena Bioscience) according to manufac-tuƌeƌ͛s iŶstƌuĐtioŶs. SpeĐtƌa Đhips ǁeƌe 
loaded into the MassArray analyzer and spectra acquired for each sample. Genotype calls were 
ŵade usiŶg TǇpeƌ ϰ.Ϭ ;AgeŶaͿ ďǇ ŵass ideŶtiﬁĐatioŶ of eǆteŶded pƌiŵeƌ peaks. 
SNP selection 
Development of custom array for Discovery Cohort: The process of selecting SNPs for the genotyping 
array involved two principal stages. First, SNPs were amalgamated based on genetic signal for 
association to a small set of phenotypes (Supplementary Table S14). The bulk of the SNPs were 
included on the basis of association results from four contrasts reported in three genome-wide 
studies: a contrast of AD+P ǀeƌsus AD − P,Ϯϵ AD+P ǀeƌsus ĐoŶtƌols,Ϯϵ AD ǀeƌsus ĐoŶtƌolsϱϱ 
(https://www.niagads.org/datasets/ng00027, 2016) and schizophrenia (SCZ) versus controls.32,56 
An additional unpublished data set (described in Lin et al.57and Seney et al.58)of cis-expression 
quantitative trait loci (cis-eQTLs) affecting gene expression and cis-eQTLs associated with age-related 
ĐhaŶges iŶ geŶe eǆpƌessioŶ ǁas also used. Foƌ the ﬁƌst fouƌ GWASs, SNPs ǁith P-value less than a 
threshold of 0.01 were selected; for the eQTLs, the thƌeshold ǁas Ϭ.ϬϬϭ aŶd foƌ the ͚agiŶg͛ eQTLs it 
was 0.05. Note that when a SNP was represented in more than one study, the minimum P-value in 
any of the 6 data sets was taken as representative for the SNP. To interrogate copy number regions 
shown to be associated with schizophrenia, 1574 SNPs were included (1q21.1, 3q29, 15q11.2-
15q13.3, 16p13.1, 16p11.2 and 22q11.2, recently reviewed in Kirov,59 and 7q11.23 (ref. 60)). Finally, 
a small fraction of SNPs were chosen to cover four genes of interest regarding psychotic disorders 
(SCZ target genes: NRXN1,59 ERBB4,61 PAK2 (ref. 62) and CHRNA7 (ref. 63)) or were nominated 
from unpublished AD studies (UK SNPs). 
Second, SNPs were retained for genotyping by a winnowing process. This process involved removing 
redundant SNPs, those that could not be genotyped on the Axiom platform or SNPs not present in 
1000 genomes. Of the SNPs passing this step, all SNPs with a minimum P-value of o0.0001 for any 
study were retained. For the remainder, by using a LD clumping process, we removed SNPs in LD 
with the retained SNPs (r240.9) and retained additional SNPs with the smallest P-value in 
͚iŶdepeŶdeŶt͛ Đluŵps ;ƌϮoϬ.ϵͿ ďǇ pƌuŶiŶg SNPs ǁith PliŶkϲϰ ;ŵaǆiŵuŵ distaŶĐe foƌ pƌuŶiŶg ǁas ϱ 
kb, window width was 25 SNPs and sliding step was 5 SNPs). 
SNP selection for SCZ risk score testing and follow-up genotyping in Replication Cohort. For SCZ risk 
sĐoƌe testiŶg iŶ eaĐh Đohoƌt ǁe taƌgeted the ϭϮϴ GWA sigŶiﬁĐaŶt SNPs ƌepoƌted iŶ SĐhizophƌeŶia 
Working Group of the Psychiatric Genomics Consortium,30 although not all could be genotyped. 
Follow-up genotyping in the Replication Cohort also selected SNPs from our custom array that 
passed QC aŶd ǁith PoϬ.ϬϬϬϭ foƌ the ĐoŶtƌast of AD+P ǀeƌsus AD − P. Foƌ the ‘epliĐatioŶ Cohoƌt ǁe 
selected ancestry-informative markers for European Ancestry based on the results in Kosoy et al.65 
SpeĐiﬁĐallǇ, ďased oŶ ƌesults fouŶd iŶ SuppleŵeŶtaƌǇ Taďle ϭ of KosoǇ et al.,ϲϱ ǁe seleĐted theiƌ 
͚Top ϵϲ͛ EuƌopeaŶ aŶĐestƌǇ-informative markers, of which 82 could be genotyped on the Sequenom 
platform and 79 passed QC. 
Quality control 
QC ǁas peƌfoƌŵed at the iŶdiǀidual leǀel ﬁƌst, aŶd theŶ at the SNP leǀel ĐoŶditioŶal oŶ iŶdiǀidual-
level data passing QC and individuals of European ancestry. Details of QC are given in Supplementary 
Materials. In brief, genetic data for samples were retained if their nominal sex agreed with 
genetically determined sex (Supplementary Figure S1); heterozygosity rate, per subject, revealed no 
evidence of contamination by other samples; genetic data for subjects expected to be unrelated 
suggested this were true; and call rate of SNPs 496.5% per sample. Next ancestry of subjects in the 
Discovery Cohort was determined using dacGem in GemTools66 based 
on 5712 autosomal markers with non-call rate င 0.001, minor allele frequency စ 0.05 and r2 င 0.20 
(Supplementary Figure S2). The samples  
 
Figure 2. Discovery (a) and replication (b) analysis of Alzheimer disease with psychosis (AD+P) risk 
single-nucleotide polymorphisms (SNPs).(a) A total of 67 SNPs reached Po5e–4 in stage 2 samples 
(dashed line). (b) Stage 3 examined 60 of the 67 SNPs, 3 of which (top blue circles, Table 3) 
appƌoaĐhed sigŶiﬁĐaŶĐe iŶ ŵeta-aŶalǇsis ;P = ϭ.ϲϭ × ϭϬ − ϲͿ. In blue, SNPs showing same risk allele in 
stages Ϯ aŶd ϯ; ƌed, stage Ϯ ǀeƌsus ϯ ƌesults diffeƌ iŶ sigŶ ;ƌisk alleleͿ; size of ĐiƌĐle ƌeﬂeĐts ŵeta-
analysis –log10(P). 
ǁeƌe sepaƌated iŶto ϱ Đlusteƌs ďased oŶ ϯ sigŶiﬁĐaŶt aŶĐestƌǇ diŵeŶsioŶs, fouƌ of ǁhiĐh likely 
ƌepƌeseŶt EuƌopeaŶ aŶĐestƌǇ aŶd tǁo of these ĐoŶtaiŶ the ďulk of the suďjeĐts ;≈ ϲϲ%Ϳ. SNP QC ǁas 
performed on data from these two clusters. SNPs passed QC if their call rate was 495%, minor allele 
frequency was စ 0.01 and the exact Hardy–Weinberg equilibrium P-value was 40.005. Ancestry of 
samples in the Replication Cohort was determined using GemTools based on 79 autosomal ancestry-
iŶfoƌŵatiǀe ŵaƌkeƌs. The saŵples sepaƌated iŶto thƌee Đlusteƌs ďased oŶ tǁo sigŶiﬁĐaŶt aŶĐestƌǇ 
dimensions (Supplementary Figure S3). 
Statistical analysis 
Association between diagnosis and minor allele count for each SNP was assessed using logistic 
ƌegƌessioŶ. Foƌ the DisĐoǀeƌǇ Cohoƌt, the ŵodel also aĐĐouŶted foƌ ﬁƌst ﬁǀe aŶĐestƌǇ diŵeŶsioŶs, 
whereas for the Replication Cohort it accounted for two. Because some subjects in the Discovery 
Cohort were related as siblings, inference relied on the generalized estimating equation (gee) 
approach implemented in the statistical software R,67 assuming full siblings were correlated at 0.5 
;that is, tǁiĐe the kiŶship ĐoefﬁĐieŶt foƌ full siďliŶgsͿ. 
To predict affection status using polygenic risk scores, either unweighted or weighted risk scores 
could be computed: the unweighted score for a subject is the sum of the count of risk alleles over all 
genotypes for that subject; a weighted score uses the same principle, but the count of risk alleles per 
SNP is adjusted by a function of the estimated effect of the SNP on risk (log odds ratio). Both 
unweighted and weighted scores for AD+P risk were calculated. Scores were derived from results 
from the Discovery Cohort and then used to predict AD+P status based on genotypes for each 
subject in the Replication Cohort. For the SCZ-ƌisk sĐoƌe, oŶlǇ a suďset of the ϭϮϴ GWA sigŶiﬁĐaŶt 
SNPs could be genotyped. For genotyped SNPs, an unweighted score for each AD subject was 
estimated. 
RESULTS 
Association of AD+P with novel common variants 
Not all of the subjects genotyped on the Axiom array were independent of our previously reported 
GWAS meta-analysis.29 Of the 2876 Discovery Cohort subjects described in Table 1a, 1157 of these 
subjects were in our prior GWAS and the remainder, 1799 suďjeĐts ;ϵϲϵ AD+P aŶd ϳϱϬ AD − PͿ, ǁeƌe 
independent. We, therefore, evaluated association both as a joint analysis of the sample sets (mega-
analysis) and by analysis of the independent subjects. For the former, we used the traditional 
thƌeshold foƌ GWAS sigŶiﬁĐaŶĐe, ϱ × ϭϬ − ϴ; foƌ the latteƌ, ǁe used a soŵeǁhat ŵoƌe leŶient 
threshold-ďased saŵple sizes aŶd the Ŷuŵďeƌ of SNPs tested oŶ ďoth saŵples ;ϱ.ϲ × ϭϬ − ϴͿ. 
For neither the joint analysis (Figure 2a) nor the independent analysis threshold (results not shown) 
ǁas aŶǇ SNP sigŶiﬁĐaŶtlǇ assoĐiated ǁith ƌisk foƌ AD+P. Foƌ the joint analysis there were 67 SNPs 
ǁith Poϱ×ϭϬ− ϰ ;Figuƌe ϮaͿ. To test these SNPs ǁe eŵpaŶeled a ‘epliĐatioŶ Cohoƌt ;Taďle ϭďͿ. We 
successfully designed and assayed either the SNP or a proxy in perfect LD for 60/67 target SNPs. We 
next used the results fƌoŵ the DisĐoǀeƌǇ Cohoƌt to assigŶ the ͚ƌisk allele͛ at eaĐh of the ϲϬ SNPs. 
Then, by counting the number of risk alleles carried by subjects in the Replication Cohort, we formed 
aŶ uŶǁeighted ƌisk sĐoƌe foƌ eaĐh suďjeĐt. This sĐoƌe sigŶiﬁĐaŶtlǇ pƌediĐted AD+P status in the 
Replication Cohort, showing clear evidence for association (Table 2a). The same is true for a 
weighted score (Table 2a).   
Moƌeoǀeƌ, although Ŷo siŶgle SNP ǁas sigŶiﬁĐaŶtlǇ assoĐiated ǁith ƌisk foƌ AD+P ǁithiŶ oƌ aĐƌoss 
stages, and only three SNPs appƌoaĐhed iŶdiǀidual sigŶiﬁĐaŶĐe ǁheŶ ĐoŵďiŶiŶg stages ;Figuƌe Ϯď 
and Table 3), 41 out of the 60 SNPs had the same risk allele for both the Discovery and Replication 
Cohoƌts ;Figuƌe Ϯď; Fisheƌ͛s eǆaĐt test, P = Ϭ.ϬϬϲϮͿ. The thƌee SNPs that appƌoaĐhed sigŶiﬁĐaŶĐe aƌe 
in RP11-ϱϰϭPϵ.ϯ ;aŶ aŶtiseŶse tƌaŶsĐƌiptͿ loĐated ϱ′ to CǇĐliŶ Gϭ ;CCNGϭͿ. 
Association of AD+P with polygenic variation associated with schizophrenia 
We pƌeǀiouslǇ desĐƌiďed a sigŶiﬁĐaŶt assoĐiatioŶ ďetǁeeŶ AD+P aŶd a suŵŵaƌǇ statistiĐ from a 
small number of putative schizophrenia and bipolar disorder risk alleles. Curiously, however, the 
direction of risk for most alleles was opposite in AD+P.29 Recently, 128 genome-ǁide sigŶiﬁĐaŶt 
SNPs at ϭϬϴ iŶdepeŶdeŶt loĐi haǀe ďeeŶ ideŶtiﬁed iŶ sĐhizophrenia.30 When these loci were 
combined into a polygenic risk score, they explained ~ 3.4% of the variance in schizophrenia risk.30 
We successfully genotyped 101 of these SNPs in the Discovery Cohort. We found that the 
corresponding unweighted risk score ǁas sigŶiﬁĐaŶtlǇ assoĐiated ǁith AD+P ;Nagelkeƌke͛s pseudo-
R2 = 0.32%, P = 0.006). We then genotyped the schizophrenia SNPs in the Replication Cohort. For 
this analysis, 94 SNPs remained after QC. Results clearly replicated, with close agreement between 
the two cohorts (Table 2b). 
Of note, as in our earlier report,29 increasing schizophrenia polygenic risk score was associated with 
reduced risk of psychosis in AD. Consider, for example, its relationship within the Discovery Cohort. 
To better illustrate this relationship, we calculated an AD+P aligned risk score. For each of the SNPs 
comprising the schizophrenia polygenic risk score, the allele that increased the risk of developing 
AD+P was determined and a weighted sum of risks was then computed for each of the samples. The 
ĐoƌƌelatioŶ ďetǁeeŶ the AD+P aligŶed ƌisk sĐoƌes aŶd the sĐhizophƌeŶia ƌisk sĐoƌes ǁas − Ϭ.ϭϱϵ ;P = 
ϱ.ϱe − ϭϴ, Figuƌe ϯͿ. 
It should be noted that despite the overall protective effects of schizophrenia polygenic risk score on 
AD+P risk, a smaller number of individual schizophrenia risk SNPs were associated with increased 
ƌisk of AD+P. Taďle ϰa details the ϮϬ SNPs that ŵost ĐoŶsisteŶtlǇ ;as deﬁŶed ďǇ the ŵiŶiŵuŵ of the 
suŵ of theiƌ iŶdiǀidual SNP ƌegƌessioŶ ĐoefﬁĐieŶts fƌoŵ the aŶalǇsis of the Discovery and Replication 
Cohorts) were associated with reduced AD+P risk. Table 4b provides similar information for the 10 
SNPs that most consistently were associated with increased AD+P risk in the two cohorts. 
DISCUSSION 
Psychosis occurs in approximately half of individuals affected by AD, serving to identify a subgroup 
with more rapid decline and poor outcomes. We, and others, have hypothesized that common 
genetic variation may contribute to the risk of psychosis in AD, based in part on evidence that AD+P 
aggregates in families, with an estimated heritability of 61%. However, prior studies of the 
association of common genetic variation with AD+P have been inconclusive.68,69 We now provide 
the ﬁƌst Đleaƌ eǀideŶĐe iŶ suppoƌt of aŶ assoĐiatioŶ of AD+P ǁith both a unique set of common 
variants and with a set of common variants associated with risk for schizophrenia.  Several potential 
methodologic issues in determining the psychosis phenotype are important to consider in evaluating 
ouƌ ﬁŶdiŶgs. Fiƌst, the Ŷeed to aggƌegate ŵultiple Đohoƌts so as to haǀe sufﬁĐieŶt poǁeƌ foƌ 
detection of association with common genetic variation meant that we included sites in which 
different rating scales were used for ascertainment of psychosis that could have contributed noise to 
ouƌ pheŶotǇpiĐ ĐlassiﬁĐatioŶs. SuĐh a liŵitatioŶ, if pƌeseŶt, ǁould haǀe ƌeduĐed ouƌ poǁeƌ to deteĐt 
diffeƌeŶĐes ďetǁeeŶ gƌoups. Thus, it speaks to the ƌoďustŶess of ouƌ ﬁŶdiŶgs that despite this 
potential limitation, we were able to replicate associations across two independent, somewhat 
hetero-geneous cohorts. Perhaps this result is not surprising, in that sigŶiﬁĐaŶt faŵilial aggƌegatioŶ 
of AD+P ǁas pƌeǀiouslǇ ideŶtiﬁed iŶ thƌee sepaƌate faŵilǇ Đohoƌts, eaĐh of ǁhiĐh ƌelied pƌiŵaƌilǇ oŶ 
a different behavioral rating scale.4,25,26 Second, we chose to consider delusions and hallucinations 
together as a psychosis syndrome rather than evaluate them individually. The best approach to this 
issue likely depends on the question being asked. For example, when evaluating functional 
neuroanatomy, separation of these symptoms could make most sense. However, for genetic studies, 
theƌe is suďstaŶtial suppoƌt foƌ gƌoupiŶg these sǇŵptoŵs. SpeĐiﬁĐallǇ, studies deŵoŶstƌatiŶg 
familial aggrega-tion of AD+P4,25,26 have all used this joiŶt deﬁŶitioŶ, estaďlishiŶg it as suitaďle foƌ 
genetic investigation. Similar data in support of individual psychotic symptoms do not exist. Finally, 
the relation-ships between clinical DLB diagnoses, Lewy body neuropathology and AD+P is 
complex.69,70 In brief, DLB pathology may contribute to some proportion, but clearly not account 
for most of the occurrence of AD+P. Nevertheless, all sites in the current study used standard 
diagnostic criteria to identify individuals with probable Lewy body dementia and exclude them from 
analysis (the one exception being the NIMH family study that predated the generation of DLB 
criteria, but did exclude individuals with parkinsonism or prominent early behavioral disturbance.71 
As practical evidence that these diagŶostiĐ appƌoaĐhes aƌe sufﬁ-ciently rigorous to identify AD 
separately from DLB, the sites included in the current study have successfully contributed to 
discovery of common variants for AD risk.42 
We ideŶtiﬁed a set of SNPs ǁith suggestiǀe assoĐiatioŶ ǁith AD+P in our Discovery Cohort, 
ĐoŶﬁƌŵiŶg this polǇgeŶiĐ assoĐiatioŶ ǁith AD+P iŶ aŶ iŶdepeŶdeŶt ‘epliĐatioŶ Cohoƌt. Although Ŷo 
individual SNP reached genome-ǁide sigŶiﬁĐaŶĐe iŶ the ŵeta-nalysis, the strongest associations 
were seen with three SNPs, rs300215, rs6859958 and rs999581, within a single locus. The function of 
the antisense transcript, RP11-ϱϰϭPϵ.ϯ, is Ŷot kŶoǁŶ. Hoǁeǀeƌ, it is loĐated ϱ′ to CCNGϭ aŶd is 
therefore likely to regulate CCNG1 expression. In support of this interpretation, rs6859958 and 
rs999581 have been shown to be eQTLs for CCNG1 in some tissues.72 Most cyclins activate cyclin-
dependent kinases, including CDK5, a Tau kinase that promotes phospho-Tau aggregation.73 In 
contrast, CCNG1 has been proposed to competi-tively inhibit the activation of cyclin-dependent 
kinases by other cyclins.74 Whether increased levels of Cyclin G1, the protein product of CCNG1, is 
therefore protective against pathological phosphorylation of Tau by CDK5 is not established. 
Nonetheless, in neocortex of AD subjects Cyclin G1 levels are increased in pyramidal neurons lacking 
Tau aggregates and are undetectable in those pyramidal neurons containing aggregated phospho-
Tau.75 Because the strongest brain correlate of psychosis in AD is excess phosphorylation of tau (in 
comparison with the degree of Tau phosphorylation in AD subjects without psychosis),69 CCNG1 is 
thus also a strong functional candidate for AD+P risk. 
We also ideŶtiﬁed aŶd ĐoŶﬁƌŵed aŶ assoĐiatioŶ of polǇgeŶiĐ ƌisk foƌ sĐhizophƌeŶia ǁith a ƌeduĐed 
risk of AD+P. At present, there are little convergent data from family studies to inform on the 
relationship of schizophrenia risk to AD+P.9,76 The inverse nature of the association between 
sĐhizophƌeŶia ƌisk sĐoƌe aŶd AD+P ŵaǇ seeŵ ĐouŶteƌiŶtuitiǀe at ﬁƌst. In fact, it was the 
ĐouŶteƌiŶtuitiǀe Ŷatuƌe of ouƌ ﬁŶdiŶgs that ŵotiǀated us to atteŵpt to iŶdepeŶdeŶtlǇ ƌepliĐate 
theŵ, ﬁŶdiŶg a ŶeaƌlǇ ideŶtiĐal assoĐiatioŶ iŶ a seĐoŶd laƌge Đohoƌt. IŶ ĐoŶtƌast to ouƌ ﬁndings, 
schizophrenia has been shown to share polygenic risk with a number of complex disorders, such as 
autism and bipolar illness, that may include psychotic symptoms as part of the expressed 
phenotype.77 Unlike AD+P, these are disorders of early, or late, neurodevelopment and thus do not 
occur in the context of neurodegeneration. 
 Possible genetic mechanisms underlying how the 108 schizophrenia-associated loci confer an 
increased risk of schizo-phrenia are just now emerging.78–80 How these loci may lead to reduced 
AD+P risk cannot be asserted, but a few exemplars are worth discussion. First, a locus may alter 
expression of a single gene that has effects during neurodevelopment that increase schizophrenia 
risk, but when the same altered expression occurs in a brain with an active AD neurodegenerative 
process, it is protective. For example, rs75968099 is an eQTL for LRRFIP2 (Table 4), the gene 
encoding Leucine-rich Repeat Flightless-interacting Protein 2, a regulator of Toll-like receptor 4-
ŵediated sigŶaliŶg iŶ ƌespoŶse to iŶﬂaŵŵatoƌǇ stiŵuli. Toll-like receptor 4 signaling helps activate 
ŵiĐƌoglia to Đleaƌ toǆiĐ aŵǇloid β fƌoŵ the ďƌaiŶ of aŶ AD patieŶt iŶ eaƌlǇ disease stages,ϴϭ ǁheƌeas 
microglial activation may contribute to excess synaptic elimination in development, increasing risk 
for schizophrenia.78 Second, a locus may regulate the expression of gene transcription differently 
during early neurodevelopment than in the adult brain. Such an effect has recently been described 
foƌ the sĐhizophƌeŶia ƌisk loĐus deﬁŶed ďǇ ƌsϱϱϴϯϯϭϬϴ, aŶd ŵaǇ siŵilaƌlǇ ďe pƌeseŶt at loci that 
confer opposing risks for schizophrenia and AD+P.80 A third scenario might result from the 
observation that a SNP and/or locus may be an eQTL for more than one gene. For example, the locus 
oŶ Đhƌoŵosoŵe ϭϳ deﬁŶed ďǇ ƌsϴϬϴϮϱϵϬ ǁas ƌeĐeŶtlǇ ƌepoƌted to show consistent disease and 
eQTL associations for two genes, TOM1L2 and DRG2,79 encoding Target of Myb1 Like 2 Membrane 
TƌafﬁĐkiŶg PƌoteiŶ ;TOMϭLϮͿ aŶd DeǀelopŵeŶtallǇ ‘egulated GTP-Binding Protein 2 (DRG2), 
respectively. DRG2 deactivates the early endosome regulator, Ras-related protein Rab-5A.82 Thus, it 
is strongly positioned to impact glutamate neurotransmission, a process implicated in the 
pathogenesis of schizophrenia, via effects on neurotransmitter release83 and on AMPA receptor 
internalization.84 In contrast, TOM1L2 is necessary for delivery of endosome cargo to 
autophagosomes that target protein aggregates and damaged organelles to lysosomes for 
degradation.85 The autophagy pathway is strongly implicated in the pathogenesis of AD86 and, 
more recently, of schizophrenia,87 and is also downstream of Toll-like receptor 4 signaling.88 Finally, 
we note that the above examples are not comprehensive. Other mechanisms may also contribute to 
different impacts of loci on risk for schizophrenia and AD+P. 
As iŶdiĐated iŶ Taďle ϰď, ǁe also ideŶtiﬁed SNPs that shoǁed the saŵe diƌeĐtioŶ of effeĐt foƌ 
schizophrenia and AD+P risk. Notable among these were two intronic SNPs located in CACNA1C, the 
gene encoding the voltage-dependent L-type calcium channel subunit alpha-1C. Although the 
genetic mechanism underlying these associations remains an area of active inquiry,89 convergent 
data suggest that schizophrenia is associated with reduced voltage-dependent calcium channel 
function.90–92 How reductions in voltage-dependent calcium channel function may further increase 
AD+P risk is not known, but impairments of intracellular Ca2+ homeostasis are present in AD and can 
contribute to synaptic dysfunction and cognitive impairments.93 
We recently estimated the annual incidence of psychosis in AD at 10%.40 Thus, there is an 
oppoƌtuŶitǇ to iŶteƌǀeŶe ďefoƌe psǇĐhosis oŶset if iŶdiǀidual pƌediĐtoƌs ĐaŶ ďe ideŶtiﬁed. Although 
currently no treatments are established for prevention of AD+P, selective serotonin reuptake 
inhibitors haǀe soŵe efﬁĐaĐǇ foƌ tƌeatiŶg it,ϮϮ,Ϯϯ aŶd theǇ haǀe aĐĐeptaďle toleƌaďilitǇ. NoŶphaƌŵa-
ĐologiĐ tƌeatŵeŶts ŵaǇ also offeƌ ďeŶeﬁt foƌ tƌeatiŶg AD+P ;ƌeǀieǁed iŶ Geda et al.ϵϰ aŶd Weaŵeƌ 
et al.40) and could be adapted for prevention. It is thus worth considering whether genetic variants 
that associate with psychosis may serve as biomarkers to predict AD+P risk and the associated more 
rapidly declining cognitive trajectory. Because individual SNP relative risks are typically small, 
polygenic risk scores have greater predictive power.31,95 We observed a very modest explanatory 
power of both the 60 SNP and the schizophrenia polygenic risk scores, each accounting for o1% of 
the AD+P risk. None of these effects is large enough to yield meaningful clinical prediction at 
present. Still, we note that these polygenic scores could have a different magnitude of effect on 
prediction of a related, clinically relevant construct, such as time to onset of psychosis. However, the 
development of predictive approaches would clearlǇ ďeŶeﬁt fƌoŵ the ideŶtiﬁĐatioŶ of additioŶal ƌisk 
loĐi. Neǀeƌtheless, the ĐuƌƌeŶt ﬁŶdiŶgs aƌe a step foƌǁaƌd iŶ the deǀelopŵeŶt of pƌeǀeŶtioŶ foƌ 
psychosis in AD. 
In that regard it is noteworthy that our custom array, used to evaluate the Discovery Cohort, was 
derived, in part, from the one existing GWAS of AD+P. That earlier GWAS was underpowered and 
limited in the number of loci interrogated.29 As a consequence, it is likely that many SNPs and loci 
that contribute meaningfully to AD+P risk were not tested in the current study. Despite this 
liŵitatioŶ, the ĐuƌƌeŶt studǇ pƌoǀides ĐoŶﬁƌŵatioŶ of the hǇpothesis that AD+P is assoĐiated ǁith 
common genetic variation. As such, it provides strong support for unbiased genome-wide scans of 
larger cohorts of AD+P and AD − P suďjeĐts that ǁill suƌelǇ ideŶtifǇ iŶdiǀidual AD+P ƌisk loĐi aŶd 
develop more strongly predictive polygenic risk scores. 
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 Figure 3. Relationship between schizophrenia risk score and risk of psychosis in Alzheimer disease 
(AD). Displayed are the risk scores for each subject; the score for schizophrenia uses the allele found 
to confer risk in Schizophrenia Working Group of the Psychiatric Genomics Consortium,30 whereas 
the AD+P aligned score uses the same SNPs but assigns risk according to the AD+P association 
ƌesults. ‘ed aŶd ďlue ĐiƌĐles iŶdiĐate AD+P aŶd AD − P suďjeĐts, ƌespeĐtiǀelǇ. AD − P, Alzheimer 
disease without psychosis; AD+P, Alzheimer disease with psychosis; SNP, single-nucleotide 
polymorphism. 
